N-[(ethoxyphosphinyl)methyl]glycine ethyl ester | 119834-64-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[(ethoxyphosphinyl)methyl]glycine ethyl ester
• 英文别名: N-<(ethoxyphosphinyl)methyl>glycine ethyl ester
• CAS: 119834-64-9
• 化学式: C₇H₁₆NO₄P
• 分子量: 209.182
• InChiKey: IUVUGZJKJHESED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.61
• 重原子数：
  13.0
• 可旋转键数：
  7.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  64.63
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  N-[(ethoxyphosphinyl)methyl]glycine ethyl ester 在 bee venom 作用下， 以 various solvent(s) 为溶剂， 反应 6.0h， 以96.3%的产率得到(carboxymethylamino)methyl-hydroxy-oxophosphanium
  参考文献：
  名称：

  Natchev, Ivan A., Phosphorus and Sulfur and the Related Elements, 1988, vol. 37, p. 133 - 142

  摘要：

  DOI：
• 作为产物：
  描述：

  聚合甲醛 、 ethyl phosphinate 、 甘氨酸乙酯盐酸盐 在 sodium carbonate 作用下， 以 水 、 1,2-二氯乙烷 为溶剂， 以55.1%的产率得到N-[(ethoxyphosphinyl)methyl]glycine ethyl ester
  参考文献：
  名称：

  Natchev, Ivan A., Phosphorus and Sulfur and the Related Elements, 1988, vol. 37, p. 133 - 142

  摘要：

  DOI：

文献信息

• COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS
  申请人：ARDELYX, INC.

  公开号：US20170340623A1

  公开（公告）日：2017-11-30

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract.
• US3988142A
  申请人：——

  公开号：US3988142A

  公开（公告）日：1976-10-26